CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

Patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B liver function are often excluded from clinical trials. In previous studies, overall survival for these patients treated with sorafenib was ∼3–5 months; thus, new treatments are needed. Nivolumab, alone or in combination with ip...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2021-09, Vol.75 (3), p.600-609
Hauptverfasser:	Kudo, Masatoshi, Matilla, Ana, Santoro, Armando, Melero, Ignacio, Gracián, Antonio Cubillo, Acosta-Rivera, Mirelis, Choo, Su-Pin, El-Khoueiry, Anthony B., Kuromatsu, Ryoko, El-Rayes, Bassel, Numata, Kazushi, Itoh, Yoshito, Di Costanzo, Francesco, Crysler, Oxana, Reig, Maria, Shen, Yun, Neely, Jaclyn, Tschaika, Marina, Wisniewski, Tami, Sangro, Bruno
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Adverse events Aged anti-PD-1 Aspartate aminotransferase Carcinoma, Hepatocellular - drug therapy checkpoint inhibitors Cirrhosis Clinical trials Cohort Studies Disease control Female Hepatocellular carcinoma Humans Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use immunotherapy Intravenous administration Liver cancer Liver cirrhosis liver decompensation Liver Neoplasms - drug therapy Male Middle Aged Nivolumab - pharmacology Nivolumab - therapeutic use objective response overall survival Patients Safety Solid tumors Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!